OBJECTIVES: Rheumatoid arthritis (RA) is a chronic disease characterized by inflammation of the synovial tissue leading to joint destruction. The introduction of biologic agents dramatically changed the prognosis of RA. At now there is a new class of agents, kinase inhibitors, that are approved for the therapy of RA. The aim of this Bayesian metanalysis is to compare adalimumab that is market leader in the treatment of RA with 2 kinase inhibitors, rispectively Baricitinib and Tofacitinib. METHODS: A literature search was performed to identify articles reporting data from RCTs on the efficacy of Adalimumab, Baricitinib and Tofacitinib in RA. Indirect comparison results are reported as the relative risk of response (RR), intended as the capacity of inducing DAS28 ESR <3,2 and DAS28 ESR <2,6 response for each intervention associated compared with placebo. RESULTS: A total of 7 scientific papers were identified. All agents, associated to MTX, proved to be more efficacious in inducing response response respect to placebo. When comparing results obtained by different drugs, Baricitinib proved to be the agent that represents the best choice for obtaining DAS28 ESR <3,2 response with a probability of 84,26%, while Adalimumab represents the best choice for inducing DAS28 ESR <2,6 response with a probability of 77%. Tofacitinib shows a probability lower than 1% to induce both DAS28 ESR results  CONCLUSIONS: In this Indirect comparison on RCTs on the efficacy of Adalimumab compared to 2 kinase inhibitors in RA, we identified Baricitinib and Adalimumab the more probably best choices in obtaining the result respectively of DAS28 ESR <3,2 and DAS28 ESR <2,6 response. Baricitinib seems to be a new promising intervention for the treatment of RA. Even if Toafacitinib and Baricitinib belong to the same class of kinase inhibitors, they don't shows similar efficacy.